These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34792199)

  • 21. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.
    Kelly JR; Park HS; An Y; Yarbrough WG; Contessa JN; Decker R; Mehra S; Judson BL; Burtness B; Husain Z
    Oral Oncol; 2018 Apr; 79():64-70. PubMed ID: 29598952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
    Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
    Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study.
    Hall SF; Liu FF; O'Sullivan B; Shi W; Rohland S; Griffiths R; Groome P
    Br J Cancer; 2017 Oct; 117(8):1105-1112. PubMed ID: 28829763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
    Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
    Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
    Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
    Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
    Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
    J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient.
    Connor S; Anjari M; Burd C; Guha A; Lei M; Guerrero-Urbano T; Pai I; Bassett P; Goh V
    Br J Radiol; 2022 Feb; 95(1130):20210333. PubMed ID: 34111977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
    Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
    O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
    J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy.
    Caparrotti F; O'Sullivan B; Bratman SV; Ringash J; Lu L; Bayley A; Cho J; Giuliani M; Hope A; Kim J; Waldron J; Hansen A; Goldstein D; Perez-Ordonez B; Weinreb I; Tong L; Song Y; Xu W; Huang SH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):858-867. PubMed ID: 28258893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
    Lin TA; Garden AS; Elhalawani H; Elgohari B; Jethanandani A; Ng SP; Mohamed AS; Frank SJ; Glisson BS; Debnam JM; Sturgis EM; Phan J; Reddy JP; Fuller CD; Morrison WH; Skinner HD; Rosenthal DI; Gunn GB
    Cancer; 2019 May; 125(9):1536-1546. PubMed ID: 30620385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
    Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Broughman JR; Xiong DD; Moeller BJ; Contrera KJ; Prendes BL; Lamarre ED; Ku JA; Burkey BB; Woody NM; Joshi NP; Adelstein DJ; Geiger JL; Frenkel CH; Milas ZL; Brickman DS; Sumrall AL; Carrizosa DR; Greskovich JF; Koyfman SA; Ward MC
    Cancer; 2020 Jun; 126(12):2784-2790. PubMed ID: 32167593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
    Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
    Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy.
    Alfaraj F; Craig T; Huang SH; O'Sullivan B; Su J; Bayley A; Bratman S; Cho J; Giuliani M; Kim J; Ringash J; Waldron J; Hansen A; de Almeida J; Perez-Ordonez B; Weinreb I; Tong L; Xu W; Hope A
    Oral Oncol; 2019 Oct; 97():124-130. PubMed ID: 31521053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes for potentially Resectable patients undergoing primary chemoradiation treatment for T1-T2 HPV Negative oropharyngeal squamous cell carcinoma.
    Laxague F; Fnais N; Son HY; Alzahrani F; Mymryk JS; Barrett JW; Tay KY; Leung A; Theurer J; Nichols AC; Palma DA
    Head Neck; 2024 Nov; 46(11):2789-2797. PubMed ID: 38779999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.
    Tsai CJ; McBride SM; Riaz N; Kang JJ; Spielsinger DJ; Waldenberg T; Gelblum D; Yu Y; Chen LC; Zakeri K; Wong RJ; Dunn L; Pfister DG; Sherman EJ; Lee NY
    JAMA Oncol; 2022 Mar; 8(3):364-372. PubMed ID: 35050342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.